Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BQ39

UPID:
DDX50_HUMAN

ALTERNATIVE NAMES:
DEAD box protein 50; Gu-beta; Nucleolar protein Gu2

ALTERNATIVE UPACC:
Q9BQ39; Q5VX37; Q8WV76; Q9BWI8

BACKGROUND:
The ATP-dependent RNA helicase DDX50, with alternative names DEAD box protein 50, Gu-beta, and Nucleolar protein Gu2, is integral to the RNA life cycle. It assists in unwinding RNA structures, facilitating critical processes such as translation initiation, ribosomal RNA processing, and mRNA export.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ATP-dependent RNA helicase DDX50 holds the key to unlocking new therapeutic avenues. Given its pivotal role in RNA biology, targeting DDX50 could lead to innovative treatments for diseases linked to RNA dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.